Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570395 | 0.82 | NOTUM (0.42) | NOTUMP2RY1GRIN2DGRIN3BCHRM2 | |
| SCHEMBL30448941 | 0.81 | NOTUM (0.50) | NOTUMP2RY1HTR2CCNR2 | |
| SCHEMBL13209362 | 0.81 | NOTUM (0.50) | NOTUMP2RY1HTR2CCNR2 | |
| SCHEMBL13209342 | 0.76 | ACLY (0.38) | NOTUMP2RY1HTR2CGRIN2DGRIN3B | |
| SCHEMBL30519847 | 0.76 | NOTUM (0.43) | NOTUMP2RY1HTR2CGABRA1GABRB2 | |
| SCHEMBL1451551 | 0.76 | NOTUM (0.43) | NOTUMP2RY1HTR2CGABRA1GABRB2 | |
| SCHEMBL13209376 | 0.74 | SIGMAR1 (0.42) | P2RY1ALDH1A1KDM1A | |
| SCHEMBL6334445 | 0.74 | NOTUM (0.42) | NOTUMP2RY1HTR2COPRM1GABRA1 | |
| SCHEMBL28035819 | 0.74 | NOTUM (0.42) | NOTUMP2RY1HTR2CGABRA1GABRB2 | |
| SCHEMBL28293891 | 0.74 | NOTUM (0.42) | NOTUMP2RY1HTR2CGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023808-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2015-05-05 | — | — | US | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | NOTUM 4169/4885P2RY1 1/4885HTR2C 282/4885 |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP2B6, HCCS | NOTUM 1859/4885P2RY1 2010/4885HTR2C 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.